




Our key figures


Our revenue decreased by 7.4% (-4.8% organically). We delivered a profitability of a 20.0% adjusted EBITDA margin and free cash flow of CHF 27.1 million.

Share of revenue by business unit
2025



- 26.8% Dental
- 7.6% Drug Delivery
- 3.9% Surgery
- 27.7% Industry
- 34.0% Beauty

Share of revenue by business unit
2024



- 23.9% Dental
- 9.0% Drug Delivery
- 3.7% Surgery
- 26.2% Industry
- 37.3% Beauty

Key figures

millions of CHF	2025	% of revenue	+/-% change	2024	% of revenue
Revenue	448.0	100.0%	-7.4%	483.9	100.0%
Organic revenue growth ¹⁾			-4.8%		
Gross profit	161.9	36.1%	1.4%	159.7	33.0%
Operating income (EBIT)	22.8	5.1%	76.7%	12.9	2.7%
EBITDA	78.3	17.5%	5.1%	74.5	15.4%
Adjusted EBITDA	89.7	20.0%	-3.1%	92.5	19.1%
Net income	7.0	1.6%	n/a	-6.4	-1.3%
Free cash flow (FCF)	27.1		-31.7%	39.6	
Operating net cash flow (ONCF)	40.3		-33.9%	61.0	
Capital expenditure, net (capex, net)	41.7		-5.9%	44.3	
Net debt as of December 31	216.5		5.4%	205.3	
Net debt adjusted EBITDA ratio as of December 31	2.41		8.7%	2.22	
Employees (number of full-time equivalents) as of December 31	2'574		-4.1%	2'684	

1) Adjusted for currency effects.

Stock market information

	2025	2024
Registered share (in CHF)		
– high	13.50	18.68
– low	8.34	8.28
– year-end	11.24	8.80
Market capitalization as of December 31		
– number of shares issued	41'262'370	41'262'370
– in millions of CHF	463.8	363.1
– in percentage of equity	109%	83%
P/E ratio as of December 31	71.8x	-48.7x
Dividend yield as of December 31	0.9%	5.7%

Data per share

CHF	2025	2024
Net income attributable to a shareholder of medmix Ltd	0.16	-0.18
Equity attributable to a shareholder of medmix Ltd	10.30	10.60
Ordinary dividend	0.10 ¹⁾	0.50
Payout ratio	64%	-277%
Average number of shares outstanding as of December 31	40'773'826	40'779'842

1) Proposal to the Annual General Meeting.

Shareholder structure as of December 31, 2025

Number of shares	Number of shareholders	Shareholding
1–100	2'246	0.3%
101–1'000	3'308	3.4%
1'001–10'000	1'111	7.6%
10'001–100'000	122	7.8%
More than 100'000	18	53.3%
Total registered shareholders and shares (excluding treasury shares of medmix Ltd)	6'805	72.3%

Shareholder structure as of December 31, 2024


Number of shares	Number of shareholders	Shareholding
1–100	2'485	0.3%
101–1'000	3'585	3.6%
1'001–10'000	1'019	7.0%
10'001–100'000	102	6.7%
More than 100'000	20	53.0%
Total registered shareholders and shares (excluding treasury shares of medmix Ltd)	7'211	70.6%

Global reach, local presence



Sustainability strategy and impact

Our strategy, long-standing commitments and ambitious targets are reflected in a comprehensive and pragmatic framework:



At medmix, our long-term success depends on sustainable and profitable growth and a flourishing planet. As a company with a long tradition in the world of precision instruments, we want to continue to have a positive influence on our industry by reconciling economic, social and environmental aspects and promoting sustainable practices.

We recognize our responsibility, both within the company and in the various communities where we operate. Our goal is to further strengthen our sustainability efforts and promote competitiveness and innovation. We work to minimize adverse impacts and maximize benefits, future-proof our growth and invest in building capabilities within our organization to adapt to the changing regulatory landscape.

People

As an aspiring employer of choice, we enable an inclusive workforce, develop impactful development opportunities and support employee engagement through an open and empowering culture.

We work to support our communities and our employees, whose safety is a key priority. We promote a safe and healthy work environment and are committed to eliminating hazards, reducing occupational health and safety risks for everyone present at our sites.

Planet

At medmix, we recognize the importance of taking a science-based approach to the reduction of our greenhouse gases to meet the goals of the Paris Agreement in limiting global warming to 1.5°C above pre-industrial levels.

We have a responsibility to act in tackling climate change, reducing pollution and waste, and being a good water steward to ensure a sustainable future for our planet.

Profit

We recognize that our responsibilities are not limited to delivering strong financial results. We proactively direct our resources towards innovations that contribute to more sustainable solutions.

medmix is committed to preventing corruption and has a zero-tolerance policy towards corrupt practices.

Commitments and progress

Our efforts across the three pillars are supported by initiatives such as enhanced engagement with stakeholders and further transparency in our sustainability reporting.

Our actions align with our strategic goals and enhance our preparedness for climate-related risks while positioning us to capitalize on emerging opportunities in the evolving market landscape.

We have been included in the 2026 edition of the “World’s Best Companies in Sustainable Growth”, a global ranking compiled by TIME Magazine in collaboration with data and research firm Statista. The list recognizes 500 companies worldwide that pair strong, profitable growth with demonstrable progress in environmental performance.

The distinction places medmix among an elite group of organizations that excel across three critical dimensions: revenue growth, financial stability and environmental impact, including greenhouse gas emissions, waste management, water consumption and renewable energy usage. Out of more than 4’000 global companies evaluated across all industries that transparently disclose environmental performance data, only 500 made the final list.

Below are a selection of the commitments addressing our material issues – our progress is on track:

People	Planet	Profit
<ul style="list-style-type: none"> • Any case of reasonable suspicion of child labor will be investigated and acted upon. • Continually improve the employee Lost Time Injury Frequency rate by eliminating hazards and mitigating risks. • Promote inclusion, with an initial focus on diversity. • Virtual learning and training opportunities will be offered to all employees. • Benchmark to living wages¹, ensuring any gaps from evolving standards of living are closed by 2030. 	<ul style="list-style-type: none"> • 30% reduction in absolute Scope 1, 2 and partial 3 CO_{2e} emissions² by 2025. • 80% reduction in absolute Scope 1 and 2 CO_{2e} emissions and 42% reduction in Scope 3 emissions by 2029. • 90% reduction in absolute Scope 1, 2 and 3 CO_{2e} emissions by 2050. • Net zero CO_{2e} emissions across the value chain by 2050. • 100% low-carbon electricity used by 2025. • Zero waste to landfill by 2025³. 	<ul style="list-style-type: none"> • Increase sales of sustainable⁴ products, making 15 available during 2025. • CDP Climate Change “C” score by 2025. • medmix' performance assessed through EcoVadis, with a commitment to continual improvement.

1) The wage level necessary to afford a decent standard of living for workers and their families, taking into account country circumstances and calculated for work performed during normal hours (International Labour Organization (ILO) definition).
 2) Scope 1, 2 and partial 3 (upstream categories 3 and 6).
 3) Aligned with UL Environmental Claim Validation Procedure 2799 Silver threshold.
 4) Minimum 30% reduction in CO_{2e} cradle-to-gate compared with standard product.

Leading brands

Our company is organized into two segments – Healthcare and Consumer & Industrial – and five business units:

All of our business units benefit from our diversified exposure to growing end-markets that are supported by long-term mega trends, such as the growing middle class, an aging population and the trend towards increased urbanization, homecare and sustainability.

Helping people live healthier and more confident lives

Our Healthcare segment is divided into the Dental, Drug Delivery and Surgery business units. In the Dental business unit, our customers use our mixing and delivery devices for a broad range of applications, such as prosthetics, restorations, anesthetics and aesthetics. The Drug Delivery unit offers drug delivery devices that are used to inject fertility drugs and growth hormones and to treat niche diabetes indications, osteoporosis and rare diseases. In the Surgery business unit, our mixing and delivery devices are used to inject bone tissue and to apply hemostatic sealants for internal and external wound treatment during surgical procedures.



Innovative, high-precision delivery

In our Consumer & Industrial segment, we operate through the Industry and Beauty business units. In the Industry business unit, our dispensers, cartridges and mixers are used in the construction, transportation (automotive, railways and aerospace), electronics assembly, infrastructure and DIY industries. In the Beauty unit, our micro-brushes are used for the application of makeup treatments, such as lash & brow serum or spot correctors, as well as for the application of skincare treatments such as anti-aging treatments.

We have a strong legacy of setting industry standards through the continuous launch of innovative products in the business-to-business (B2B) markets in which we operate.

